Physician profile
Frank P Barrows
NPI 1427025535
$2,718.16
in general payments reported to CMS, 2019-2025
22 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $127 · 2022: $1,483 · 2023: $390 · 2024: $162 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,538.90 | 2019-2024 | Sogroya, Wegovy |
| Medtronic Minimed, INC. | $163.68 | 2019-2020 | |
| Pfizer INC. | $114.33 | 2019-2025 | |
| Insulet Corporation | $113.20 | 2019-2025 | Omnipod |
| Abbott Laboratories | $108.41 | 2022-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $94.44 | 2023-2024 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $91.99 | 2023-2025 | Skytrofa |
| Xeris Pharmaceuticals, INC. | $88.56 | 2022-2024 | Gvoke Hypopen |
| Dexcom, INC. | $60.04 | 2019-2023 | Dexcom G6 Transmitter |
| Endo Pharmaceuticals INC. | $55.43 | 2023-2024 | Supprelin |
| Arbor Pharmaceuticals, INC. | $51.11 | 2019-2020 | |
| Abbvie INC. | $51.07 | 2020-2022 | |
| Tandem Diabetes Care, INC. | $32.65 | 2020-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $26.36 | 2020 | |
| Ferring Pharmaceuticals INC. | $24.83 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $18.02 | 2025 | |
| Eton Pharmaceuticals, INC. | $16.20 | 2023 | Alkindi |
| Alexion Pharmaceuticals, INC. | $15.62 | 2024 | Strensiq |
| Neurocrine Biosciences, INC. | $14.98 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $13.71 | 2024 | |
| Ibsa Pharma INC. | $13.02 | 2019 | |
| Sandoz INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Barrows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.